The decision to stop the therapy in genotype 1 chronic hepatitis C patients treated with PEG-IFN-a-2a and ribavirin can be confidently made after 4 weeks of treatment based on the absence of baseline anti-NS4a Ab and a week-4 hepatitis C virus-RNA above 100.000 IU/ml.
Background Early detection of nonresponders to hepatitis C therapy limits unnecessary exposure to treatment and its side-effects. A recent algorithm combining baseline anti-NS4a antibodies and on-treatment quantitative PCR identified nonresponders to a combination of interferon and ribavirin after 1 week of treatment.
Aim To validate a stopping rule based on baseline anti-NS4a antibody levels and early on-treatment virological response in treatment-naive genotype 1 chronic hepatitis C patients treated with the current standard pegylated interferon and ribavirin combination therapy.
Methods Eighty-nine genotype 1 patients from the Dynamically Individualized Treatment of hepatitis C Infection and Correlates of Viral/Host dynamics Study treated for 48 weeks with standard 180 lg pegylated interferon (PEG-IFN)-a-2a (weekly) and ribavirin 1000-1200 mg (daily) were analysed. Baseline anti-NS4a antibody enzyme-linked immunosorbent assay (NS4a AA 1687-1718) was performed on pretreatment serum. Hepatitis C virus-RNA was assessed at days 0, 1, 4, 7, 8, 15, 22 , 29, weeks 6, 7, 8, 10, 12 and 6 weekly thereafter until end of treatment. Multiple regression logistic analysis was performed.
Results Overall 54 of 89 (61%) patients achieved sustained virological response. A baseline anti-NS4a antibody titre less than 1/1250 correlated with absence of favourable initial viral decline according to variable response types (P = 0.015). The optimal algorithm was developed using the combination of the absence of anti-NS4a Ab ( < 1/1250) at baseline and the presence of a viral load Z 100.000 IU/ml at week 4. This algorithm has a specificity of 43% and negative predictive value of 100% to detect nonresponse to standard PEG-IFN-a-2a and ribavirin therapy at fourth week of therapy (intention-to-treat analysis).
Introduction
Pegylated interferon-a-2a and ribavirin (RBV) combination therapy induces a sustained virological response (SVR) in only half of the genotype 1-infected chronic hepatitis C patients [1] . Accurate early recognition of those patients who will not clear the hepatitis C virus (HCV) infection despite a full 48-week treatment course allows earlytreatment discontinuation limiting unnecessary exposure to potential side-effects. The absence of a more than 2 log drop from baseline viral load after 12 weeks of treatment detects 31% of nonresponder patients with a negative predictive value (NPV) of 97% [1, 2] . A stopping rule that would identify more nonresponder patients earlier on during the treatment would further limit the side-effects and costs of the treatment for these patients.
Recently Desombere et al. [3] developed a stopping algorithm based on the absence or presence of baseline anti-NS4a antibodies (Ab) and early on-treatment viral load (HCV-RNA Z 10 5 IU/ml) that detects nonresponse with a NPV of 100% in a group of patients treated with standard interferon and RBV combination therapy.
Our aim was to develop a stopping rule with at least similar NPV and improved specificity in comparison with the current 12-week stopping rule based on baseline anti-NS4a serology status and early on-treatment quantitative viral load in patients treated with pegylated interferon-a-2a and RBV combination therapy.
Materials and methods
The Dynamically Individualized Treatment of hepatitis C Infection and Correlates of Viral/Host dynamics (DIT-TO) HCV Study group recruited 270 chronic hepatitis C patients for an open-label phase 3 international multicenter trial [4] . Treatment-naive patients with compensated liver disease and the following characteristics were eligible: positive test for anti-HCV Ab, HCV-RNA greater than 1000 IU/ml (Cobas Amplicor HCV Monitor v 2.0 assay, Roche Diagnostics (Branchburg, NJ, USA), lower limit of detection 600 IU/ml), two serum alanine aminotransferase values above the upper limit of normal within 6 months of treatment initiation and a pretreatment (within earlier 12 months) liver biopsy consistent with a diagnosis of chronic hepatitis C. The major exclusion criteria were reported earlier [4] . Patients were randomized after 6 weeks of combination therapy with pegylated interferon-a-2a and weight-based RBV combination therapy according to initial viral kinetics of the first 4 weeks to either individualized treatment or continued standard treatment until week 48.
For this analysis, the subset of 89 genotype 1 patients who completed at least 4 weeks of therapy in the standard treatment arm were analysed. All patients were treated with weekly injections of 180 mg pegylated interferon-a-2a in combination with daily oral RBV at a dose of 1000 or 1200 mg dependent of bodyweight below or above 75 kg. All patients were motivated to continue treatment for the 48-week treatment period. Treatment could be stopped at the discretion of the investigator if HCV-RNA was still positive after 24 weeks of treatment.
Laboratory assessments
HCV-genotyping was confirmed centrally at Erasmus MC University Medical Center Rotterdam by reverse hybridization (Inno LipA HCV II; Innogenetics, Gent, Belgium). Baseline anti-NS4a enzyme-linked immunosorbent assay was determined on a pretreatment serum sample (NS4a AA 1687-1718, horseradish peroxidiselabelled goat anti-human IgG Ab; dilutions 1/10, 1/100, 1/ 250, 1/1250, 1/16250) in the CEVAC laboratory in Ghent as described earlier [3] . HCV-RNA was determined centrally in Rotterdam with the Cobas Amplicor HCV Monitor V 2.0 assay (Roche Diagnostics, lower limit of detection 600 IU/ml) at days 0, 1, 4, 7, 8, 15, 22, 29, weeks 6, 7, 8, 10 and 12 and every 6 weeks thereafter till the end of the treatment. All samples that tested negative with the quantitative assay were retested with the Cobas Amplicor HCV Monitor V 2.0 qualitative assay (Roche Diagnostics, lower limit of detection 50 IU/ml).
Definition of response type
In the DITTO study, rapid viral response (RVR) was defined as an at least 2 log drop of HCV-RNA during the first 4 weeks and a second-phase decline at least 0.09 log/ day. Slow partial response (SPR) was defined as no RVR, but a second-phase decline at least 0.09 log/day and (i) an at least 1 log drop of HCV-RNA during the first 4 weeks or (ii) an at least 0.6 log drop of HCV-RNA during the first 4 weeks and a first-phase decline of at least 0.5 log. SVR was defined as negative qualitative HCV-RNA less than 50 IU/ml at 24 weeks after the end of treatment (week 72).
Study end points and objectives
The primary objective of this study was to develop a stopping rule that reliably detects nonresponder patients during the first weeks of treatment based on the absence of pretreatment anti-NS4a Ab and the presence of a rapid on-treatment HCV-RNA decline. Two items were considered of paramount importance in the development of the stopping rule: NPV and specificity. The NPV of a stopping rule reflects the probability that the algorithm indeed predicts a true 'nonresponse', or in other words how sure one can be that no potential SVR patients will be lost by applying the early stopping rule. The specificity depicts the fraction of all nonresponding patients who will indeed be identified by the prediction criteria. The goal is the highest possible specificity with a NPV of 100%. For this study we aimed to develop a stopping rule that could detect at least a similar proportion of nonresponders as the current week 12 2 log rule, but to detect these patients at an earlier stage during treatment while maintaining excellent NPV.
Statistical analysis
Multiple logistic regression analysis was used to explore a possible correlation between nonbaseline anti-NS4a Ab titre and viral load at baseline and days 0, 1, 4, 7, 8, 15, 22, 29. All analyses were performed as intention-to-treat analysis, categorizing patients with missing week 72 data as nonsustained virological patients. Receiver operating characteristic curves and Akaike Information Criteria were used to investigate the noninferiority of specificity and NPV of a possible new stopping algorithm with the current week 12 2 log rule specificity and NPV. All analyses were performed using SPSS 12.0 statistical software (SPSS Inc., Chicago, Illinois, USA).
Results

Patient characteristics
The study population (n = 89) consisted of genotype 1-infected chronic hepatitis C patients with a mean age of 41 years (20-66), predominantly of Caucasian origin. Sixty-four percent of patients (57/89) had a high baseline viremia of at least 0.8 Â 10 6 IU/ml, and the median viremia at baseline in this study group was 1.38 Â 10 6 IU/ml. Ten percent of patients had a baseline viremia less than 10 5 IU/ml. Cirrhosis, defined as an Ishak Score of 5 or 6, was present in 10% of the patients (Table 1 ). SVR in this study group with a high baseline viremia was 61% (54/89) when treated with a standard 48 weeks pegylated interferon-a-2a and RBV combination therapy (intention-to-treat analysis). SVR was achieved in 39 of 47 (83%) and 14 of 30 (47%) patients showing RVR and SPR according to the DITTO response types, respectively. Thirty-five of 89 patients had no SVR at week 72. Of these, nine of 89 (10%) patients discontinued treatment prematurely before week 48. Fifteen of 89 patients (17%) did not achieve an end-of-treatment virological response at week 48. Relapse occurred in the remaining 11 of 89 patients (12%) at week 72.
Baseline anti-NS4a antibody levels
Logistic regression analysis showed a correlation between baseline anti-NS4a Ab levels and the initial viral kinetics. Patients with a baseline anti-NS4a Ab titre of less than 1/1250 displayed significantly fewer RVRs or SPRs compared with patients with a baseline anti-NS4a Ab titre at least 1/1250 (P = 0.015, w 2 test) ( Fig. 1 ). There was no statistically significant correlation between baseline anti-NS4a Ab levels and HCV-RNA negativity at any time point of treatment or with the SVR status at end of follow-up.
HCV-RNA at week 4
A single HCV-RNA value exceeding 10 5 IU/ml at week 4 was superior in detecting nonresponding patients early on during treatment (sensitivity 96.3%, specificity 48.6%, PPV 74.3%, NPV 89.5%) than a 2 log HCV-RNA decline at this time point. This parameter however lacked adequate NPV prohibiting its clinical application as stopping rule, as therapy would be incorrectly stopped in 10.5% of patients.
HCV-RNA at week 12
Evaluation of the current week 12 2 log stopping rule in this group showed a sensitivity of 100%, a specificity of 31%, a PPV of 69% and a NPV of 100%, confirming earlier reported values [1, 2] . In this group of 89 patients, a stopping rule based on the absence of a week 12 HCV-RNA below 1600 IU/ml had the best specificity of 43% while maintaining a NPV of 100% to predict nonresponse.
Algorithm based on early HCV-RNA determination and baseline anti-NS4a antibody titre
Multiple logistic regression analysis with the variables baseline anti-NS4a Ab titre, HCV-RNA level and treatment duration was performed (Fig. 2 ). An algorithm could be developed based on a baseline anti-NS4a Ab titre of less than 1/1250 and the presence of a HCV-RNA of at least 10 5 IU/ml after 4 weeks of treatment. Patients who had week 4 HCV-RNA of at least 10 5 IU/ml and a baseline anti-NS4a Ab titre of less than 1/1250 had no chance of achieving SVR with continued treatment. This algorithm had a sensitivity of 100%, specificity of 43%, PPV of 73% and NPV of 100% to detect nonresponse to standard pegylated interferon-a-2a RBV combination therapy after 4 weeks of therapy (intention-to-treat analysis). The performance of this stopping rule is similar in the group of 80 of 89 patients with a baseline HCV-RNA at least 10 5 IU/ml as all patients with a week 4 HCV-RNA less than 10 5 IU/ml are to continue therapy with this rule (sensitivity 100%, specificity 43%, PPV 69%, NPV 100%). Our week-4 stopping rule categorized seven of the nine drop-out patients as week 4 responders. The week 4 algorithm has a sensitivity of 100%, specificity of 50%, PPV of 81% and NPV of 100% in 80 of 89 patients who continued per weeks of treatment in this study group (Fig. 3 ).
Discussion
The aim of this study was to develop a clinical applicable stopping rule that would allow earlier detection of nonresponse compared with the current week 12 2 log stopping rule while maintaining a reliable NPV and detecting at least a similar proportion of nonresponder patients. The combination of a low anti-NS4a Ab titre at baseline, correlating with a low likelihood of favourable initial viral kinetics, and HCV-RNA determination at week 4, constitutes a stopping rule with adequate NPV and specificity. This stopping rule detects at least a similar proportion of nonresponders as the week 12 2 log rule, but does so 8 weeks earlier.
Careful examination of the three variables used in this analysis, namely HCV-RNA level, treatment duration and baseline anti NS4a Ab titre revealed the following trends. The earlier the time point, the better the specificity and PPV, but the worse the sensitivity and NPV for a given HCV-RNA cutoff or log decline value. This translates into the clinical knowledge that the presence of early ontreatment HCV-RNA negativity favours subsequent SVR, but is not an absolute requirement as a number of patients who achieve HCV-RNA negativity later than week 4 still become sustained responders with continued treatment. This prevents the development of a clinically relevant stopping algorithm based on a single qualitative HCV-RNA level alone before week 12. In this cohort, 96.3% of responder patients had a week 4 HCV-RNA below 10 5 IU/ml, the cutoff put forward in Desombere's algorithm [3] . In patients treated with pegylated interferon this cutoff has clinical relevance after 4 weeks treatment duration, whereas in Desombere's study in patients treated with short acting standard interferon this cutoff value seemed to be useful already after 1 week of therapy. The NPV of 90% of the week 4 HCV-RNA cutoff of 10 5 IU/ml is insufficient to be used as a reliable stopping rule. We were able to increase the NPV of an early on-treatment qualitative HCV-RNA level by adding a baseline parameter to our algorithm. Our findings corroborate those of Desombere et al. [3] in that decreasing baseline anti-NS4a Ab levels correlate with the absence of a favourable initial viral response to pegylated interferon and RBV combination treatment. The mechanism underlying this association is unclear at present. It has recently been shown that the HCV NS3/4a protease interferes with the innate immune response against HCV infection by abrogation of the RIG1 and TLR3 pathway [5] [6] [7] . It has also been shown that interferon nonresponders have high baseline interferon stimulated genes status without any further increase upon interferon administration compared with interferon responders [8] . We speculate that the counteractive interaction of the NS3/4a protease with the innate immune system and the interferon stimulated genes status response is abrogated in the presence of a high titre of anti-NS4a specific Ab resulting in both better innate response and more favourable viral response to exogenous administered interferon.
Many baseline factors have been described that correlate with a lower probability to obtain SVR in genotype 1 Week 4 stopping rule
Week 12 patients with pegylated interferon and RBV treatment. Among these high viral load, advanced fibrotic stage, Afro-American descendance, high BMI and presence of steatosis are recognized baseline factors that make SVR less likely [9, 10] . Low IP10 interferon gamma inducible protein [11, 12] , baseline homozygosity for the promoter diplopy of ACC-IL10 in non-Hispanic Caucasian patients [13] , and IL28B CC genotype regardless of descendance [14, 15] correlate with a higher probability to achieve SVR in adherent patients. The presence of baseline factors statistically in disfavour for SVR does not obviate the possibility to achieve SVR in a given patient completely.
Withholding therapy on the basis of any of these parameters is thus unjustified and the need for early accurate on-treatment detection of nonresponse remains of paramount importance. Our new week 4 stopping rule is based on the presence of a baseline factor that correlates with favourable initial viral kinetics on the one hand, baseline level of anti-NS4a Ab, and ontreatment HCV-RNA on the other as direct reflection of interferon response and indirect reflection of patient adherence. Our new paradigm will be easy to apply in current practice as week 4 HCV-RNA determinations have become custom management in most centres. This algorithm has a higher specificity and hence detects a larger proportion of nonresponding patients early on during treatment compared with a recently proposed stopping rule that is based on the absence of a 2 log viral decline and week 4 HCV-RNA greater than 5.5 log IU/ml [16] . It is important that the new week 4 stopping rule has a 100% NPV and will thus stop therapy only in true nonresponders. All patients in this study were offered treatment for 48 weeks, irrespective of the week 12 HCV-RNA results, with the possibility to stop treatment if week 24 HCV-RNA was positive. The new stopping rule is therefore valid for the true occurrence of SVR or no SVR.
Our findings are based on data of a moderate-size group and ideally are to be validated in the framework of larger patient groups. It is likely that our stopping rule will need adaptations with the advent of new future direct antiviral agent treatment regimes, since the majority of genotype 1 patients treated with these regimes have undetectable HCV-RNA after 4 weeks of combination therapies with these new agents [17, 18] .
In conclusion, a baseline anti-NS4a Ab titre of less than 1/1250 in combination with a week 4 PCR of at least 10 5 IU/ml reliably detects nonresponse to 48 weeks of pegylated interferon and RBV therapy with a NPV of 100% and does so 8 weeks earlier than the current week 12 2 log rule.
